2022 American Transplant Congress
The Role Of Gut Microbiome In Optimum Dose Selection Of Tacrolimus For Kidney Transplant Recipients
1George Mason University, Arlington, VA, 2George Washington University Hospital, Washington, DC
*Purpose: This study aims to validate and apply a personalized optimal dose selection model for Tacrolimus (Tac) for kidney transplant recipients at the George Washington…2022 American Transplant Congress
Thymoglobulin Induction Protocol: Quality Improvement Project via Clinical Audit
*Purpose: The aim of our study was to analyze the adequacy of the thymoglobulin (rATG) induction protocol for the expanding and higher complexity kidney transplant…2022 American Transplant Congress
Post-Kidney Transplant Valacyclovir or Valganciclovir for EBV Prophylaxis: A Randomized Controlled Trial
*Purpose: EBV viremia post-kidney transplant (KTx) has no proven prophylaxis.*Methods: In this randomized, open-label trial [NCT01329185], adult and pediatric recipients were randomly assigned (1:1) to…2022 American Transplant Congress
Optimal Dose of Anti-Thymocyte Globulin to Improve Allograft and Patient Survival After Kidney Transplantation: Analysis from Korean Organ Transplantation Registry Data
Surgery, Asan Medical Center, Seoul, Seoul, Korea, Republic of
*Purpose: The optimal dose of anti-thymocyte globulin (ATG) as an induction regimen in Asian kidney recipients is unclear.*Methods: Using Korean Organ Transplantation Registry database, we…2022 American Transplant Congress
Reduction of Rabbit Anti-Thymocyte Globulin Dosing for Induction of Kidney Transplant During the COVID-19 Pandemic
*Purpose: Rabbit anti-thymocyte globulin (rATG) is a polyclonal antibody utilized for induction immunosuppression in high immunologic risk kidney transplant recipients. However, the optimal total dose…2022 American Transplant Congress
Real-Life Tacrolimus Levels Are Associated with Biopsy-Proven Acute Rejection After the First Year Post-Kidney Transplantation
*Purpose: Evidence to recommend specific target concentrations for immunosuppression beyond the first year of kidney transplantation (KT) is limited. We correlated real-life exposure data of…2022 American Transplant Congress
Conversion of Tacrolimus Immediate Release to LCP Tacrolimus in Obese Kidney Transplant Recipients
*Purpose: Data describing the safety, efficacy and conversion ratio of tacrolimus immediate release (IR) to LCP-tacrolimus (LCP) in obese patients (BMI > 30) is lacking.…2022 American Transplant Congress
Artificial Intelligence Based Dosing of Tacrolimus in Liver Transplantation: Prospective, Randomized Phase 2 Trial
*Purpose: Inter- and intra-individual variability in calcineurin dose requirements necessitates empirical clinician-titrated dosing that frequently results in deviation from target ranges, particularly during the critical…2022 American Transplant Congress
Use of Dd-cfdna to Guide Tapering of Immunosuppression Therapy in Kidney Transplant Recipients
1Victoria Kidney and Dialysis Associates, Victoria, TX, 2Natera, Inc., Austin, TX
*Purpose: Continuous administration of immunosuppressive therapy (IST) is required to avoid allograft rejection in transplant recipients. However, these therapeutic interventions can lead to significant side…2022 American Transplant Congress
Incidence of Dapsone-Induced Methemoglobinemia in Solid Organ Transplant Recipients
*Purpose: The purpose of this study was to determine the incidence of dapsone-induced methemoglobinemia in solid organ transplant recipients.*Methods: This was a single-center retrospective cohort…
- 1
- 2
- 3
- …
- 9
- Next Page »